Daniel M. Canafax

Daniel M. Canafax

Chief Tech/Sci/R&D Officer at XWPharma Ltd.

71 year
Health Technology
Consumer Services

Profile

Daniel M.
Canafax
is currently the Chief Medical Officer at XWPharma Ltd.
He previously held positions as Director at MedImmune LLC, Vice President-Medical Affairs & Clinical Research at Omeros Corp., Chief Development Officer & Vice President at ARYx Therapeutics, Inc., Vice President-Clinical Development at XenoPort, Inc., Vice President-Clinical Development at Innoviva, Inc., and Vice President-Clinical Development at Theravance Biopharma, Inc. He also worked as a Professor at the University of Minnesota.
Canafax holds a doctorate from the University of Kentucky and an undergraduate degree from Washington State University.

Daniel M. Canafax active positions

CompaniesPositionStart
Chief Tech/Sci/R&D Officer 2018-09-09
All active positions of Daniel M. Canafax

Former positions of Daniel M. Canafax

CompaniesPositionEnd
THERAVANCE BIOPHARMA, INC. Corporate Officer/Principal 2017-01-31
ARYX THERAPEUTICS, INC. Corporate Officer/Principal 2010-01-31
XENOPORT, INC. Chief Tech/Sci/R&D Officer 2007-01-31
Director/Board Member 2002-06-30
Corporate Officer/Principal -
See the detail of Daniel M. Canafax's experience

Training of Daniel M. Canafax

Washington State University Undergraduate Degree
University of Kentucky Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Daniel M. Canafax's experience

Connections

63

1st degree connections

10

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies4
ARYX THERAPEUTICS, INC.

Health Technology

INNOVIVA, INC.

Health Technology

OMEROS CORPORATION

Health Technology

THERAVANCE BIOPHARMA, INC.

Health Technology

Private companies3

Health Technology

Health Technology

Health Technology

See company connections
  1. Stock Market
  2. Insiders
  3. Daniel M. Canafax
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW